CN103889411B - 用于调节代谢途径的组合物和方法 - Google Patents

用于调节代谢途径的组合物和方法 Download PDF

Info

Publication number
CN103889411B
CN103889411B CN201280045267.1A CN201280045267A CN103889411B CN 103889411 B CN103889411 B CN 103889411B CN 201280045267 A CN201280045267 A CN 201280045267A CN 103889411 B CN103889411 B CN 103889411B
Authority
CN
China
Prior art keywords
composition
leucine
resveratrol
antiaging
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280045267.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103889411A (zh
Inventor
麦克·泽梅尔
E·道格拉斯·格林德斯塔夫二世
安提亚·布鲁克鲍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nusirt Sciences Inc
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Priority to CN201810151437.3A priority Critical patent/CN108114285A/zh
Priority to CN201810140657.6A priority patent/CN108261547A/zh
Publication of CN103889411A publication Critical patent/CN103889411A/zh
Application granted granted Critical
Publication of CN103889411B publication Critical patent/CN103889411B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
CN201280045267.1A 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法 Expired - Fee Related CN103889411B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810151437.3A CN108114285A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法
CN201810140657.6A CN108261547A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201161508139P 2011-07-15 2011-07-15
US61/508,139 2011-07-15
US201261636597P 2012-04-20 2012-04-20
US201261636605P 2012-04-20 2012-04-20
US201261636603P 2012-04-20 2012-04-20
US201261636610P 2012-04-20 2012-04-20
US201261636608P 2012-04-20 2012-04-20
US201261636598P 2012-04-20 2012-04-20
US61/636,608 2012-04-20
US61/636,597 2012-04-20
US61/636,603 2012-04-20
US61/636,598 2012-04-20
US61/636,610 2012-04-20
US61/636,605 2012-04-20
PCT/US2012/046814 WO2013012760A1 (en) 2011-07-15 2012-07-13 Compositions and methods for modulating metabolic pathways

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201810140657.6A Division CN108261547A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法
CN201810151437.3A Division CN108114285A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法

Publications (2)

Publication Number Publication Date
CN103889411A CN103889411A (zh) 2014-06-25
CN103889411B true CN103889411B (zh) 2018-03-16

Family

ID=47519040

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280045267.1A Expired - Fee Related CN103889411B (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法
CN201810140657.6A Pending CN108261547A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法
CN201810151437.3A Pending CN108114285A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810140657.6A Pending CN108261547A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法
CN201810151437.3A Pending CN108114285A (zh) 2011-07-15 2012-07-13 用于调节代谢途径的组合物和方法

Country Status (16)

Country Link
US (9) US8623924B2 (https=)
EP (2) EP2731599B1 (https=)
JP (2) JP6158801B2 (https=)
KR (1) KR20140054066A (https=)
CN (3) CN103889411B (https=)
AU (2) AU2012284267B2 (https=)
BR (1) BR112014000895A2 (https=)
CA (1) CA2841748C (https=)
HK (2) HK1250656A1 (https=)
IL (1) IL230467B (https=)
MX (1) MX2014000419A (https=)
PH (1) PH12014500198A1 (https=)
RU (2) RU2631597C2 (https=)
SG (1) SG10201609673QA (https=)
WO (1) WO2013012760A1 (https=)
ZA (1) ZA201400553B (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623924B2 (en) 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
EP2875359A4 (en) * 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
CN105101958B (zh) * 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
WO2014111580A1 (en) * 2013-01-18 2014-07-24 Procell Sprl Urolithin b for muscle growth
MX370090B (es) 2013-02-01 2019-10-25 Centro De Investig En Alimentacion Y Desarrollo A C Un método y un sistema para el tratamiento integral de aguas residuales de una industria del maíz.
HK1220391A1 (zh) * 2013-03-14 2017-05-05 Abbott Laboratories 与长期体力活动不足有关的胰岛素抗性的治疗
WO2014149280A1 (en) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
CN105228627B (zh) * 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
EP3054938A1 (en) 2013-10-09 2016-08-17 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
US9138453B2 (en) * 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
EP3110507B1 (en) * 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
JP6309343B2 (ja) * 2014-05-21 2018-04-11 協和発酵バイオ株式会社 ３−ヒドロキシ−３−メチル酪酸カルシウム含有錠剤およびその製造方法
EP3197437A4 (en) * 2014-09-24 2018-05-23 NuSirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
ITMI20141843A1 (it) * 2014-10-27 2016-04-27 Giovannini Luca Associazioni sinergiche stimolanti l¿espressione di sirtuina 1
CN107405503A (zh) * 2014-12-19 2017-11-28 光环生命科学有限公司 鞣花酸二水合物在药物制剂中调节血糖水平的用途
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
AU2016227767A1 (en) * 2015-03-03 2017-07-27 Société des Produits Nestlé S.A. Compound use in promoting energy expenditure
CN104771327B (zh) * 2015-03-11 2017-09-12 广州健坤生物科技有限公司 一种具有激活hsf‑1转录功能的组合物及其用途
WO2016151372A1 (en) * 2015-03-21 2016-09-29 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
JP2018515153A (ja) 2015-04-10 2018-06-14 ケダリオン セラピューティックス，インコーポレイテッド 交換式アンプルを備えた圧電式ディスペンサ
DK3302704T3 (da) 2015-06-01 2023-02-13 Metabolic Tech Inc Sammensætninger og fremgangsmåder til anvendelse af beta-hydroxy-beta-methylbutyrat (hmb) til reduktion af fedtmasse
US10285963B2 (en) * 2015-06-08 2019-05-14 Horacio Astudillo de la Vega Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
PT3349745T (pt) * 2015-09-16 2024-03-18 Metabolic Tech Inc Composições e métodos de utilização de beta-hidroxi-beta metilbutirato (hmb) para melhorar a recuperação de traumatismos de tecidos moles
EP3369419B1 (en) * 2015-10-30 2024-08-28 Yasumasa Kato Composition for treating diabetes
US11701336B2 (en) 2015-10-30 2023-07-18 Yasumasa Kato Method of determining composition effective for treating diabetes
CN106854643B (zh) * 2015-12-08 2021-01-26 台湾粒线体应用技术股份有限公司 植物萃取物用于提升粒线体活性的用途
BR112018014920A2 (en) * 2016-01-21 2018-12-18 Metabolic Technologies, Inc. methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
US11406609B2 (en) 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
CN121177244A (zh) * 2016-05-25 2025-12-23 技源集团股份有限公司 包含3-羟基-3-甲基丁酸的软凝胶胶囊剂
KR102412086B1 (ko) 2017-01-20 2022-06-22 켄달리온 테라퓨틱스 인코포레이티드 압전 유체 분배기
JP6895309B2 (ja) * 2017-05-11 2021-06-30 理研ビタミン株式会社 Ａｍｐｋ活性促進用組成物
US20200306231A1 (en) * 2017-10-26 2020-10-01 Vershalee Shukla Oral hypoglycemic agents as food additives and supplements
WO2019113483A1 (en) 2017-12-08 2019-06-13 Kedalion Therapeutics, Inc. Fluid delivery alignment system
CN108324929B (zh) * 2018-03-09 2021-07-13 深圳市容大生物技术有限公司 一种减少体脂率及体脂反弹的组合物及其制备方法和应用
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
CN108642001B (zh) * 2018-05-08 2022-09-02 中国农业科学院北京畜牧兽医研究所 一种提高牛性控冻精体外受精能力的方法
WO2020010116A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
CN108837154B (zh) * 2018-08-31 2021-05-07 中国药科大学 一种细胞膜仿生脂蛋白靶向纳米递药系统的制备及应用
US11701335B2 (en) * 2018-08-31 2023-07-18 Apr Applied Pharma Research S.A. Methods of normalizing amino acid metabolism
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
CN109517848A (zh) * 2018-11-01 2019-03-26 沈阳农业大学 具有抗灰葡萄孢菌活性的dhis的制备方法和应用
WO2020092877A1 (en) * 2018-11-02 2020-05-07 The Children's Hospital Of Philadelphia Modulation of mitochondrial biogenesis by increase in iron sulfur cluster activity
CN109521118A (zh) * 2018-12-18 2019-03-26 广西壮族自治区兽医研究所 一种同时测定桃金娘果中4种酚类物质的方法
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US11219612B2 (en) 2019-06-11 2022-01-11 Dremcubed, Llc Nutraceutical formulation for unblocking receptors
WO2021096882A1 (en) * 2019-11-11 2021-05-20 Nusirt Sciences, Inc. Compositions, methods and kits for altering adipocytes
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
US20210145764A1 (en) * 2019-11-15 2021-05-20 Brigham Young University Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
AU2021216555B2 (en) * 2020-02-05 2024-11-14 DailyColors Health Inc. Compositions and methods for nutritional supplements
US12090087B2 (en) 2020-04-17 2024-09-17 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CN115768384A (zh) 2020-04-17 2023-03-07 科达隆治疗公司 流体动力致动的不含防腐剂分配系统
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CN115884769A (zh) 2020-09-04 2023-03-31 雀巢产品有限公司 用于向动物提供健康益处的组合物和方法
EP4210709B1 (en) 2020-09-14 2025-10-29 Pharma Cinq, LLC 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112836621B (zh) * 2021-01-29 2022-11-08 华东理工大学青岛创新研究院 一种植物细胞表型检测方法及系统
CA3211454A1 (en) * 2021-02-21 2022-08-25 Pharma Cinq, Llc Compositions and compounds for co-delivery of uridine and ketoleucine
CN116171162A (zh) * 2021-08-26 2023-05-26 南京纽邦生物科技有限公司 用于增强线粒体生物发生和激活PGC-1α的组合物和方法
WO2023048878A1 (en) * 2021-09-24 2023-03-30 The Trustees Of Indiana University Depletion of fndc5 reduces cancer induced muscle loss/cachexia
CN113698384B (zh) * 2021-10-26 2022-01-18 上海维京生物医药科技有限公司 阿格列汀没食子酸盐及其制备方法和应用
WO2025137462A1 (en) * 2023-12-21 2025-06-26 Numiera Therapeutics Inc. Combination therapy for cancer
WO2025213072A1 (en) * 2024-04-04 2025-10-09 University Of Massachusetts Supercharging therapeutic adipocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1761405A (zh) * 2003-03-18 2006-04-19 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007650A (en) 1911-05-13 1911-10-31 Wesley Ellis Belt-guide.
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
JPH03219838A (ja) 1989-11-06 1991-09-27 Itochu Shiryo Kk 体脂肪の蓄積量を減少させる飼料
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
FI951218A0 (fi) * 1992-09-16 1995-03-15 Univ Iowa State Res Found Inc Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
DE69723812D1 (de) 1996-01-09 2003-09-04 Riken Wako Aminosäurezusammensetzungen
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE69707413T3 (de) 1997-01-09 2009-07-02 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
HUP0101890A2 (hu) 1998-05-04 2001-10-28 Andreas Johannes Kesel Monomer, oligomer és polimer knoevenagel-kondenzációs termékek
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
JP2003529347A (ja) 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド 高齢ペット用の栄養補給食品
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US8398546B2 (en) 2000-06-16 2013-03-19 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
JP2002047699A (ja) 2000-07-31 2002-02-15 Toto Ltd 給水の配管システム
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
TWI329516B (en) 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
ES2311482T3 (es) 2000-12-29 2009-02-16 Martin Francis Gannon Producto alimenticio para animales.
PL363426A1 (en) 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
CA2466415C (en) 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., a novel pgc-1 homologue and uses therefor
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
US20040009216A1 (en) 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
EP3173082A1 (en) 2002-05-17 2017-05-31 Duke University Method for treating obesity
MXPA05000224A (es) 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20050181097A1 (en) 2002-09-16 2005-08-18 Mars, Inc. Nutritionally complete pet food and method of feeding and manufacturing same
RU2335927C2 (ru) 2002-09-20 2008-10-20 Новартис Аг Обогащенные лейцином питательные композиции
AU2003275491A1 (en) 2002-10-09 2004-05-04 Bodymedia, Inc. Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) * 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
AU2004221875B2 (en) * 2003-03-13 2010-11-11 Vector Usa Inc. A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
JP4353982B2 (ja) 2003-05-14 2009-10-28 インダス バイオテック ピーブイティ． エルティーディー． 糖尿病処置用相乗作用組成物
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
FR2856407B1 (fr) 2003-06-19 2007-10-12 Inst Nat Sante Rech Med Procede de production d'une proteine recombinante d'interet et proteine produite
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
US7502643B2 (en) 2003-09-12 2009-03-10 Bodymedia, Inc. Method and apparatus for measuring heart related parameters
ATE547951T1 (de) 2003-11-03 2012-03-15 Hills Pet Nutrition Inc Überzogene tierfutterzusammensetzung
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
EP1685833A1 (en) * 2003-11-21 2006-08-02 Ajinomoto Co., Inc. Remedy for diabetes
CN1886061B (zh) 2003-11-26 2011-11-16 希尔氏宠物营养品公司 减少伴侣动物排泄物气味的方法
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
CA2569015A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20070244202A1 (en) 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
JP4785140B2 (ja) 2004-08-04 2011-10-05 国立大学法人東京海洋大学 脂質代謝調節作用を有する食品素材、健康食品、動物用飼料及び動物の飼育方法
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
WO2006023975A2 (en) 2004-08-24 2006-03-02 Depuy Mitek, Inc. Expandable needle suture apparatus and associated handle assembly with rotational suture manipulation system
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252314B2 (en) 2004-09-24 2012-08-28 Hill's Pet Nutrition, Inc. Hypoallergenic composition
CA2588818A1 (en) 2004-11-29 2006-06-01 Toyo Shinyaku Co., Ltd. Athletic ability enhancing composition
EP1832284A4 (en) * 2004-12-28 2008-07-30 Ajinomoto Kk INDUCER OR SECRETAGOGUE OF ADIPONECTIN
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
PL1845994T3 (pl) 2005-02-11 2009-07-31 Pulmagen Therapeutics Synergy Kombinacja związków metyloksantyny i steroidów do leczenia przewlekłych chorób układu oddechowego
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
JP2008535790A (ja) 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
ES2376114T3 (es) 2005-05-13 2012-03-09 Nestec S.A. Producción de glucosamina a partir de especies vegetales.
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2007039367A (ja) 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070092577A1 (en) 2005-10-03 2007-04-26 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
RU2414897C2 (ru) 2005-11-30 2011-03-27 Нестек С.А. Способы лечения потери мышечной массы
AU2006320167C1 (en) 2005-12-02 2011-04-07 Hill's Pet Nutrition, Inc. Methods for altering stool quality and/or stool frequency
US20090136588A1 (en) 2005-12-02 2009-05-28 Hill's Pet Nutrition, Inc. Methods For Altering Food Intake, Modifying Nutrient Digestibility and Altering Stool Quality and/or Stool Frequency
JPWO2007069744A1 (ja) * 2005-12-16 2009-05-28 味の素株式会社 メタボリックシンドローム予防・改善用組成物
BRPI0706448A2 (pt) 2006-01-10 2011-03-29 Hills Pet Nutrition Inc método, composição e kit para promover perda de gordura em um animal adulto, meio para comunicar informação sobre ou instruções para usar uma dieta, e, uso de lisina
WO2007100722A2 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
JP5222482B2 (ja) * 2006-04-07 2013-06-26 花王株式会社 脂肪分解促進剤
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP2015644A1 (en) 2006-05-10 2009-01-21 DSMIP Assets B.V. Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
CA2672420A1 (en) * 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
CA2675638C (en) 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
EP2126828A4 (en) 2007-02-16 2012-01-25 Bodymedia Inc SYSTEMS AND METHODS FOR UNDERSTANDING AND APPLYING THE PHYSIOLOGICAL AND CONTEXTUAL LIFE PATTERNS OF ONE OR MORE INDIVIDUALS
ATE468025T1 (de) 2007-02-23 2010-06-15 Hills Pet Nutrition Inc Zusammensetzungen und verfahren für die gewichtskontrolle bei tieren
WO2008115563A1 (en) 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
US7850997B2 (en) * 2007-03-21 2010-12-14 Tim Romero Dietary compositions and methods of enhancing lean body mass and exercise performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
BRPI0810719A8 (pt) 2007-04-30 2016-03-08 Abbott Lab Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
JPWO2008143182A1 (ja) 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
JP5121308B2 (ja) * 2007-05-28 2013-01-16 ハウスウェルネスフーズ株式会社 メタボリックシンドロームの予防、改善または治療組成物
WO2008153945A2 (en) 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
WO2008157537A2 (en) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
US20100130597A1 (en) 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
US8088043B2 (en) 2007-09-07 2012-01-03 Nike, Inc. Wearable device assembly having athletic functionality
US7820618B2 (en) * 2007-10-04 2010-10-26 Northern Innovations and Formulations Energy status of an individual by enhanced usage of an endogenous fuel source
KR20100084156A (ko) 2007-10-22 2010-07-23 더 코카콜라 컴파니 중성화된 주스류 음료 및 이의 제조 방법
WO2009054994A2 (en) 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
RU2440771C1 (ru) 2007-12-21 2012-01-27 Хилл'С Пет Ньютришн, Инк. Состав кормового продукта для домашних животных (варианты)
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
MX2010008376A (es) 2008-02-04 2011-02-22 Mercury Therapeutics Inc Moduladores ampk.
EP3352107B1 (en) 2008-03-03 2025-10-22 NIKE Innovate C.V. Interactive athletic equipment system
AU2009225721B2 (en) 2008-03-17 2014-02-13 The Procter & Gamble Company. User-customizable dosing system
JP5645809B2 (ja) 2008-04-02 2014-12-24 ナイキ イノベイト セー． フェー． 運動用機能を有するウェアラブルデバイスアセンブリ
EP2308493A4 (en) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
WO2010009478A2 (en) 2008-07-18 2010-01-21 Hill's Pet Nutrition, Inc. Compositions and methods for treating disorders associated with overweight animals
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
AU2009282482B2 (en) 2008-08-15 2015-11-26 Société des Produits Nestlé S.A. Methods for enhancing energy metabolism
FR2938732B1 (fr) * 2008-11-21 2011-04-01 Holymark Composition nutritive pour sportif, en particulier pour pratiquant d'une activite physique superieure a une heure.
AU2009322474A1 (en) 2008-12-01 2011-07-21 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
CA2760158C (en) 2009-04-26 2016-08-02 Nike International Ltd. Gps features and functionality in an athletic watch system
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
JP2012527894A (ja) 2009-05-28 2012-11-12 ザ・アイムス・カンパニー 被覆キブル形態のペットフード
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
JP2013500010A (ja) 2009-07-21 2013-01-07 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 愛玩動物の栄養系
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
EP2477620A1 (en) 2009-09-18 2012-07-25 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
CN102053946B (zh) 2009-10-30 2014-05-28 国际商业机器公司 多核系统中处理请求的数据处理方法、设备和系统
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
DK2512236T3 (en) * 2009-12-18 2017-01-16 Metabolic Tech Inc IMPROVED PROCEDURE FOR ADMINISTRATION OF BETA-HYDROXY-BETA-METHYL BUTYRATE (HMB)
AU2010343129B2 (en) 2009-12-29 2013-05-16 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
CN102695428A (zh) 2010-01-06 2012-09-26 雀巢产品技术援助有限公司 用于模拟热量限制的膳食方案
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
EP2564858A4 (en) 2010-04-28 2013-10-30 Nihon Pharmaceutical Co Ltd COMPOSITION FOR THE TREATMENT OF ASTHENOPIA
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
US8623924B2 (en) 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
HK1199378A1 (en) 2011-08-19 2015-07-03 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
CN105101958B (zh) 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
WO2014149280A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
EP3054940B1 (en) 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
EP3197437A4 (en) 2014-09-24 2018-05-23 NuSirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
WO2017040407A1 (en) 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1761405A (zh) * 2003-03-18 2006-04-19 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids

Also Published As

Publication number Publication date
CA2841748A1 (en) 2013-01-24
HK1251146A1 (zh) 2019-01-25
JP2014520864A (ja) 2014-08-25
KR20140054066A (ko) 2014-05-08
US20150342914A1 (en) 2015-12-03
EP2731599A4 (en) 2015-04-08
US9682053B2 (en) 2017-06-20
US9198883B1 (en) 2015-12-01
US8617886B2 (en) 2013-12-31
EP2731599A1 (en) 2014-05-21
AU2012284267A1 (en) 2014-01-30
PH12014500198A1 (en) 2017-02-10
HK1250656A1 (zh) 2019-01-11
JP2017160258A (ja) 2017-09-14
AU2012284267B2 (en) 2017-06-29
US9072692B2 (en) 2015-07-07
IL230467B (en) 2020-07-30
US9351967B2 (en) 2016-05-31
RU2014105552A (ru) 2015-08-27
SG10201609673QA (en) 2017-01-27
US20130017283A1 (en) 2013-01-17
RU2017129378A (ru) 2019-02-04
CA2841748C (en) 2021-06-15
WO2013012760A1 (en) 2013-01-24
US9855235B2 (en) 2018-01-02
US20130017284A1 (en) 2013-01-17
MX2014000419A (es) 2014-09-22
US20160113915A1 (en) 2016-04-28
JP6158801B2 (ja) 2017-07-05
AU2017213477A1 (en) 2017-08-31
CN108114285A (zh) 2018-06-05
US20170312240A1 (en) 2017-11-02
BR112014000895A2 (pt) 2019-08-06
EP2731599B1 (en) 2018-10-31
CN103889411A (zh) 2014-06-25
CN108261547A (zh) 2018-07-10
IL230467A0 (en) 2014-03-31
US20190224152A1 (en) 2019-07-25
HK1198925A1 (en) 2015-06-19
RU2631597C2 (ru) 2017-09-25
US20140148488A1 (en) 2014-05-29
ZA201400553B (en) 2018-07-25
US8623924B2 (en) 2014-01-07
US10076507B1 (en) 2018-09-18
US20160338983A1 (en) 2016-11-24
EP3466418A1 (en) 2019-04-10
US10383837B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
CN103889411B (zh) 用于调节代谢途径的组合物和方法
CN104918610B (zh) 用于增强能量代谢的组合物和方法
HK1198925B (en) Compositions and methods for modulating metabolic pathways

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198925

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180316